Publications by authors named "D Mazzetti"
Article Synopsis
- Glioblastoma is a highly aggressive brain tumor with a median survival of only 6-9 months after progression, due to factors like molecular pathways and tumor microenvironment.
- Current treatments like surgery, radiation, and chemotherapy can manage the primary tumor but not effectively prevent relapse, and the role of surgery for recurrent cases is debated.
- New innovative therapies for recurrent glioblastoma are being developed, including checkpoint inhibitors and CAR T-cell therapy, aimed at improving treatment outcomes.
The lack of reliable predictive biomarkers to guide effective therapy is a major obstacle to the advancement of therapy for high-grade gliomas, particularly glioblastoma (GBM), one of the few cancers whose prognosis has not improved over the past several decades. With this pilot clinical trial (number NCT04135807), we provide first-in-human evidence that drug-releasing intratumoral microdevices (IMDs) can be safely and effectively used to obtain patient-specific, high-throughput molecular and histopathological drug response profiling. These data can complement other strategies to inform the selection of drugs based on their observed antitumor effect in situ.
View Article and Find Full Text PDF